

Kadcyla® (ado-trastuzumab emtansine) – New indication

- On May 3, 2019, <u>Genentech announced</u> the FDA approval of <u>Kadcyla (ado-trastuzumab emtansine)</u>, as a single agent, for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and <u>Herceptin[®] (trastuzumab)</u>-based treatment.
 - Select patients for therapy based on an FDA-approved companion diagnostic for Kadcyla.
- Kadcyla is also approved as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer (MBC) who previously received Herceptin and a taxane, separately or in combination. Patients should have either:
 - Received prior therapy for metastatic disease, or
 - Developed disease recurrence during or within six months of completing adjuvant therapy.
- The efficacy of Kadcyla for HER2-positive, EBC was demonstrated in an open-label study (KATHERINE) of 1,486 patients. Patients received Kadcyla or Herceptin. The major efficacy outcome of the study was invasive disease-free survival (IDFS).
 - After a median follow-up of 40 months, a statistically significant improvement in IDFS was observed in patients who received Kadcyla vs. Herceptin. A total of 12.2% of Kadcyla patients experienced an event vs. 22.2% of Herceptin treated patients (Hazard ratio = 0.50 [95% CI: 0.39, 0.64]; p < 0.0001)
- Kadcyla carries a boxed warning for hepatotoxicity, cardiac toxicity, and embryo-fetal toxicity.
- The recommended dose of Kadcyla is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle). Kadcyla should not be administered at doses greater than 3.6 mg/kg.
 - Herceptin should not be substituted for or with Kadcyla.
 - Patients with EBC should receive treatment for a total of 14 cycles unless there is disease recurrence or unmanageable toxicity.
 - Patients with MBC should receive treatment until disease progression or unmanageable toxicity.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.